Schedule 13G ownership disclosure
Protalix BioTherapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 74365A309
Event date: 2026-03-24
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- MAK Capital Fund LP
Shares: 3,616,289.00 · Class: 4.5%
- MAK CAPITAL ONE LLC
Shares: 3,616,289.00 · Class: 4.5%
- Kaufman Michael A
Shares: 3,616,289.00 · Class: 4.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001426156-26-000006
- Form type
- SCHEDULE 13G/A
- Filer
- MAK Capital Fund LP
- CIK
- CIK 1426156
- Filed
- Mar 30, 2026
- Reporting period
- Mar 24, 2026
- Description
- Schedule 13G beneficial ownership